2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.
Barata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason G, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Lerner S, Balzer-Haas N, Pal S. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal Of Clinical Oncology 2024, jco2400767. PMID: 39255440, DOI: 10.1200/jco.24.00767.Peer-Reviewed Original ResearchAdvanced papillary renal cell carcinomaPapillary renal cell carcinomaRenal cell carcinomaOverall survivalCell carcinomaProlonged progression-free survivalLack of survival benefitProgression-free survivalRandomized phase IIMedian follow-upPrimary end pointOpen-label trialOverall survival analysisCrizotinib armMedian OSSurvival benefitClinical trial updateNo significant differenceCabozantinibTreatment armsSunitinibFollow-upClinical trialsSavolitinibCrizotinibPathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma
Tripathi A, Tangen C, Plets M, Li X, Tretiakova M, Humphrey P, Adeniran A, Barata P, Gulati S, Bergerot C, Pruthi D, Thompson I, Lara P, Lerner S, Pal S, Shuch B. Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU International 2024, 134: 596-601. PMID: 39014969, DOI: 10.1111/bju.16403.Peer-Reviewed Original ResearchPapillary renal cell carcinomaPositive predictive valueRenal cell carcinomaLocal pathology reviewCentral reviewPathology reviewCell carcinomaAdvanced papillary renal cell carcinomaMetastatic papillary renal cell carcinomaPapillary renal cell carcinoma subtypesPatients treated with targeted therapyExpert genitourinary pathologistsPathological concordance rateLocal reviewGenitourinary pathologistsClinical benefitCabozantinibClinical significanceClinical valueSubtype assignmentConcordance rateType 1CarcinomaPatientsPredictive valueSarcomatoid and Rhabdoid Renal Cell Carcinoma
Adeniran A, Shuch B, Humphrey P. Sarcomatoid and Rhabdoid Renal Cell Carcinoma. The American Journal Of Surgical Pathology 2024, 48: e65-e88. PMID: 38736105, DOI: 10.1097/pas.0000000000002233.Peer-Reviewed Original ResearchRenal cell carcinomaSarcomatoid renal cell carcinomaGenomic alterationsRhabdoid differentiationRhabdoid cellsCell carcinomaWHO classification of renal tumorsClassification of renal tumorsInternational Collaboration on Cancer ReportingHistologic types of renal cell carcinomaPleomorphic undifferentiated sarcomaMalignant spindle cellsAggressive biological behaviorMolecular featuresMolecular mechanisms of tumorigenesisMechanisms of tumorigenesisSarcomatoid growthRhabdoid componentSarcomatoid componentRhabdoid featuresRenal tumorsClinical responseCollege of American PathologistsRhabdoid morphologySarcomatoid elements
2023
Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.
Tripathi A, Tangen C, Li X, Tretiakova M, Humphrey P, Adeniran A, Barata P, Gulati S, Bergerot C, Pruthi D, Thompson I, Lara P, Pal S, Shuch B. Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial. Journal Of Clinical Oncology 2023, 41: 4562-4562. DOI: 10.1200/jco.2023.41.16_suppl.4562.Peer-Reviewed Original ResearchProgression-free survivalPositive predictive valueCentral pathology reviewCentral reviewPathology reviewHistologic subtypeType 1PRCC subtypesAdvanced papillary renal cell carcinomaPathologic concordance rateLines of therapyPapillary renal cell carcinomaSubset of patientsType 2 tumorGreater clinical benefitRenal cell carcinomaLimited clinical valueType 2 diseaseExpert genitourinary pathologistsLocal reviewClassification of subtypesSunitinib armMET alterationsClinical outcomesClinical benefit
2022
An update on computational pathology tools for genitourinary pathology practice: A review paper from the Genitourinary Pathology Society (GUPS)
Parwani A, Patel A, Zhou M, Cheville J, Tizhoosh H, Humphrey P, Reuter V, True L. An update on computational pathology tools for genitourinary pathology practice: A review paper from the Genitourinary Pathology Society (GUPS). Journal Of Pathology Informatics 2022, 14: 100177. PMID: 36654741, PMCID: PMC9841212, DOI: 10.1016/j.jpi.2022.100177.Peer-Reviewed Original Research
2018
Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies
Martin DT, Ghabili K, Levi A, Humphrey PA, Sprenkle PC. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies. Urology 2018, 125: 64-72. PMID: 30552940, DOI: 10.1016/j.urology.2018.12.001.Peer-Reviewed Original ResearchConceptsPI-RADSv2 scoreDecipher scoreProstate Imaging ReportingDecipher testingTargeted biopsiesRadical prostatectomyData System version 2 (PI-RADS v2) scoreFavorable intermediate-risk prostate cancerIntermediate-risk prostate cancer patientsGleason Grade Group 1Imaging ReportingIntermediate-risk prostate cancerMultivariable logistic regression analysisHigh-risk diseasePI-RADS 4Grade group 1Gleason grade groupProstate cancer patientsMultiparametric magnetic resonancePI-RADS scoreVersion 2 scoreData System scoreLogistic regression analysisSignificant differencesPI-RADS categoryGenomic Heterogeneity and the Small Renal Mass
Ueno D, Xie Z, Boeke M, Syed J, Nguyen KA, McGillivray P, Adeniran A, Humphrey P, Dancik GM, Kluger Y, Liu Z, Kluger H, Shuch B. Genomic Heterogeneity and the Small Renal Mass. Clinical Cancer Research 2018, 24: 4137-4144. PMID: 29760223, PMCID: PMC6125159, DOI: 10.1158/1078-0432.ccr-18-0214.Peer-Reviewed Original Research
2017
Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy
Lu AJ, Syed JS, Nguyen KA, Nawaf CB, Rosoff J, Spektor M, Levi A, Humphrey PA, Weinreb JC, Schulam PG, Sprenkle PC. Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy. Urology 2017, 105: 118-122. PMID: 28322902, DOI: 10.1016/j.urology.2017.01.048.Peer-Reviewed Original ResearchConceptsMultiparametric magnetic resonance imagingSignificant prostate cancerProstate cancerNegative predictive valueMagnetic resonance imagingSystematic TRUSNegative mpMRIProstate biopsyNegative multiparametric magnetic resonance imagingPredictive valueResonance imagingClinically Significant Prostate CancerDynamic contrast enhancement sequencesTemplate mapping biopsyPrior negative biopsySystematic prostate biopsyOverall cancer detectionProstate-specific antigenTemplate prostate biopsyProstate cancer detectionDiffusion-weighted imagingCancer detectionBiopsy naïveMapping biopsyProstate volume
2016
Testis
Brimo F, Srigley J, Ryan C, Choyke P, Humphrey P, Barocas D, Brookland R, Buyyounouski M, Fine S, Halabi S, Hamstra D, Kattan M, McKenney J, Mason M, Oh W, Pettaway C, Touijer K, Zelefsky M, Sandler H, Amin M, Lin D. Testis. 2016, 735-743. DOI: 10.1007/978-3-319-40618-3_59.Peer-Reviewed Original ResearchKonsenskonferenz 2014 der ISUP zur Gleason-Graduierung des Prostatakarzinoms
Kristiansen G, Egevad L, Amin M, Delahunt B, Srigley J, Humphrey P, Epstein J, Graduierungskommittee. Konsenskonferenz 2014 der ISUP zur Gleason-Graduierung des Prostatakarzinoms. Die Pathologie 2016, 37: 17-26. PMID: 26809207, DOI: 10.1007/s00292-015-0136-6.Peer-Reviewed Original ResearchThe incidence of adverse pathologic characteristics in small renal masses as size increases.
Nawaf C, Rosoff J, Adeniran A, Humphrey P, Shuch B. The incidence of adverse pathologic characteristics in small renal masses as size increases. Journal Of Clinical Oncology 2016, 34: 596-596. DOI: 10.1200/jco.2016.34.2_suppl.596.Peer-Reviewed Original ResearchAdverse pathologic featuresRenal cell carcinomaActive surveillanceLymphovascular invasionPathologic featuresRenal massesAdverse pathologic characteristicsCT1a renal massesHistologic tumor necrosisRenal tumor biopsySelection of patientsSingle-institution databaseType II histologyHigh nuclear gradeTumor size categoriesSmall renal massesSignificant increaseSarcomatoid featuresPathologic characteristicsTumor sizeCell carcinomaPrimary tumorAUA guidelinesHistologic characteristicsLarge tumorsMRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy.
Nawaf C, Lu A, Rosoff J, Weinreb J, Schulam P, Humphrey P, Levi A, Sprenkle P. MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy. Journal Of Clinical Oncology 2016, 34: 90-90. DOI: 10.1200/jco.2016.34.2_suppl.90.Peer-Reviewed Original ResearchPrior negative biopsyCS cancerGleason scoreNegative MRIProstate cancerNegative biopsyCS prostate cancerMRI suspicion scoreMRI-US fusionPre-biopsy mpMRIFusion prostate biopsyMRI-ultrasound fusionSignificant prostate cancerCancer detection rateBiopsy of lesionsMaximum Gleason scoreMulti-parametric MRIElevated PSAPrevious biopsyRepeat biopsyMapping biopsyBiopsy resultsProstate biopsyFusion biopsyStandard biopsy
2015
NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence
Manda K, Tripathi P, Hsi A, Ning J, Ruzinova M, Liapis H, Bailey M, Zhang H, Maher C, Humphrey P, Andriole G, Ding L, You Z, Chen F. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence. Oncogene 2015, 35: 3282-3292. PMID: 26477312, PMCID: PMC5012433, DOI: 10.1038/onc.2015.389.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlotting, WesternCell LineCell Line, TumorCell ProliferationCell Transformation, NeoplasticCellular SenescenceCytokinesGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMice, KnockoutMice, NudeMice, TransgenicNFATC Transcription FactorsProstateProstatic NeoplasmsPTEN PhosphohydrolaseReverse Transcriptase Polymerase Chain ReactionTransplantation, HomologousTumor Cells, CulturedTumor MicroenvironmentConceptsProstate tumorigenesisHuman PCaNFATc1 activationNon-tumorigenic prostate cellsActivated T cells c1Cultured PCa cellsT cells c1Cellular senescenceRole of NFATc1Number of cytokinesActivation of NFATc1Proinflammatory cytokinesPCa cellsProstate cancerProstatic adenocarcinomaLuminal epitheliumMouse prostateCells c1Normal prostateOncogenic roleOncogene c-mycProstate tissueProstate cellsSoluble factorsNuclear factor
2014
PD19-12 MODIFIED GLEASON GRADE OF PROSTATIC ADENOCARCINOMAS DETECTED IN THE PROSTATE, LUNG, COLORECTAL, AND OVARIAN CANCER SCREENING TRIAL
Humphrey P, Strother M, Grubb R, Hickey T, Korch M, Riley T, Mabie J, Bellinger A, Andriole G. PD19-12 MODIFIED GLEASON GRADE OF PROSTATIC ADENOCARCINOMAS DETECTED IN THE PROSTATE, LUNG, COLORECTAL, AND OVARIAN CANCER SCREENING TRIAL. Journal Of Urology 2014, 191: e550. DOI: 10.1016/j.juro.2014.02.1531.Peer-Reviewed Original Research
2012
Foamy Gland Adenocarcinoma of the Prostate: Incidence, Gleason Grade, and Clinical Outcome
Hudson J, Cao D, Vollmer R, Kibel A, Grewal S, Humphrey P. Foamy Gland Adenocarcinoma of the Prostate: Incidence, Gleason Grade, and Clinical Outcome. American Journal Of Clinical Pathology 2012, 138: a108-a108. DOI: 10.1093/ajcp/138.suppl1.103.Peer-Reviewed Original Research
2009
Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis
Song H, Zhang B, Watson M, Humphrey P, Lim H, Milbrandt J. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene 2009, 28: 3307-3319. PMID: 19597465, PMCID: PMC2746257, DOI: 10.1038/onc.2009.181.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAtrophyClusterinDisease Models, AnimalDisease ProgressionDown-RegulationGene DeletionGene Expression ProfilingGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansLasersMaleMiceMicrodissectionOxidoreductases Acting on Sulfur Group DonorsProstateProstatic NeoplasmsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mycPTEN PhosphohydrolaseSignal TransductionThioredoxinsTranscription FactorsTranscription, GeneticTranscriptional ActivationConceptsNKX3.1 lossMolecular consequencesGene expressionProstate tumorigenesisPTEN-AKTCancer initiationProstate cancer initiationCohort of genesNumber of genesC-Myc signaling pathwayDownstream target genesHuman prostate tumorigenesisLoss of NKX3.1NKX3.1 expressionTumor suppressor geneGene expression data setsExpression data setsQuiescin Q6Transcriptional regulatorsIndependent lossesExpression of NKX3.1Laser capture microdissectionTarget genesCancer gene expression data setsSignaling pathwaysA PROSPECTIVE STUDY OF FDG-PET/CT FOR DETECTING OCCULT METASTATIC BLADDER CARCINOMA
Katz M, Dehdashti F, Grubb R, Humphrey P, Gao F, Siegel C, Klim A, Siegel B, Kibel A. A PROSPECTIVE STUDY OF FDG-PET/CT FOR DETECTING OCCULT METASTATIC BLADDER CARCINOMA. Journal Of Urology 2009, 181: 376. DOI: 10.1016/s0022-5347(09)61063-6.Peer-Reviewed Original ResearchEVALUATION OF URETERAL PHYSIOLOGIC CHANGES WITH A NOVEL “RIBBON STENT” DESIGN USING ELECTROMYOGRAPHIC AND GIANT MAGNETORESISTIVE SENSORS
Natalin R, Hruby G, Okhunov Z, Singh H, Phillips C, Humphrey P, Gupta M, Landman J. EVALUATION OF URETERAL PHYSIOLOGIC CHANGES WITH A NOVEL “RIBBON STENT” DESIGN USING ELECTROMYOGRAPHIC AND GIANT MAGNETORESISTIVE SENSORS. Journal Of Urology 2009, 181: 663-664. DOI: 10.1016/s0022-5347(09)61861-9.Peer-Reviewed Original Research
2008
Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue
Brimo F, Vollmer R, Corcos J, Kotar K, Bégin L, Humphrey P, Bismar T. Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. Histopathology 2008, 53: 177-183. PMID: 18752501, DOI: 10.1111/j.1365-2559.2008.03087.x.Peer-Reviewed Original ResearchConceptsPathological stageTumor lengthPrognostic valueTumor extentFinal pathological stageHigher stage diseaseNeedle biopsy specimenCancer patient outcomesPrognostic significanceBiochemical recurrenceBiopsy specimenRadical prostatectomyPatient outcomesBiopsy reportingFailure statusCancer lengthPositive coresPathological outcomesLarger studyMorphometric measurementsDiscontinuous fociCancerCore tissuePatientsOutcomesHISTOLOGIC RECLASSIFICATION OF BENIGN AND MALIGNANT RENAL TUMORS USING 2004 WHO CRITERIA
Skolarus T, Serrano M, Bullock T, Grubb R, Gao F, Humphrey P, Kibel A. HISTOLOGIC RECLASSIFICATION OF BENIGN AND MALIGNANT RENAL TUMORS USING 2004 WHO CRITERIA. Journal Of Urology 2008, 179: 380. DOI: 10.1016/s0022-5347(08)61113-1.Peer-Reviewed Original Research